CA-NEXA3D
Nexa3D, the leading maker of ultrafast professional and industrial polymer 3D printers, today announced its plans to exhibit at IMTS, taking place September 12-17 in Chicago, Illinois. For its first showing at IMTS, Nexa3D is bringing its full – and rapidly expanding - additive manufacturing portfolio to Chicago.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005132/en/
The full suite of Nexa3D additive manufacturing solutions will be showcased at IMTS 2022, Additive Manufacturing Pavilion, Booth #432504 (Photo: Business Wire)
Among the real-world use cases highlighted at the booth will be the work with Applied Rapid Technologies (ART), where Nexa3D will demonstrate the benefits of owning the industrial 3D printing fleet for an on-demand manufacturing operation that replaces traditional urethane casting. Ultrafast, high performance resin 3D printing enables companies like ART to serve its customers’ needs in a more cost-effective manner and at a fraction of the time typically associated with traditional manufacturing methods. “Being a service provider with the Nexa3D machines - having 8 of them online now - just gives us more flexibility to take on projects and turn them around quickly. For years, we called this rapid prototyping, but it has really morphed into additive manufacturing,” said Bruce LeMaster, Vice President of Manufacturing at Obsidian Solutions Group.
“Nexa3D’s rapidly expanding product portfolio of ultrafast industrial solutions for the entire product life cycle democratizes access to industrial strength additive manufacturing tools, materials, and workflows for the benefit of small and large users. With no end in sight to persisting supply chain shortages, small and large product companies are more ready than ever before to explore digital manufacturing solutions and we are here to assist,” said Avi Reichental, CEO, and co-founder of Nexa3D.
Nexa3D’s end-to-end validated workflows, comprising its NexaX software platform, expanding functional polymer materials, and automated post processing deliver orders of magnitude better throughput and total cost of ownership advantages to businesses that are seeking to nearshore or localize parts of their supply chain operations. The company plans to showcase its latest industrial shop printers including its flagship NXE 400 and NXE 200 ultrafast 3D printers alongside its xCure, and xClean post-processing tools. The company also plans to introduce several new functional resins at the show.
As part of its rapidly expanding portfolio of manufacturing solutions, Nexa3D also plans to demonstrate the full power of its ultrafast XiP 3D printer in a production cell configuration, showcasing industry leading throughput, cost effectiveness, and functional material selection, powered by its open source platform enabling hyperlocal, flexible manufacturing.
The company plans to commercially launch previously announced QLS 820 high-productivity industrial sintering solution along with a powder processing system at IMTS. Designed for higher operating temperatures and broader powder processing windows, the QLS 820 offers the highest part throughput in its class, delivering unprecedented production throughput and flexibility. The system is a compelling alternative to traditional injection molding, designed with integration-ready Industry 4.0, lights-out manufacturing capabilities.
Nexa3D plans to take center stage on Wednesday, Sept. 14 at 1:00PM alongside its customer, PepsiCo, to talk about the latest manufacturing innovations in packaging design and development made possible by its ultrafast NXE 400 3D printers. More information and registration details available here.
As part of IMTS, the company plans to make several significant product commercialization announcements throughout the week from the show floor.
To learn more about the additive manufacturing solutions Nexa3D plans to exhibit at IMTS view the media kit.
About Nexa3D
Nexa3D is passionate about digitizing supply chains sustainably. The company makes ultrafast polymer 3D printers that deliver up to 20x productivity gains to professionals and businesses of all sizes. Partnerships with world-class material suppliers and its open materials platform unlock the full potential of additively manufactured polymers for volume production. Automated software tools optimize the entire production cycle using process interplay algorithms that ensure part performance and production consistency, while reducing waste, energy, and minimizing carbon footprints.
For more information on Nexa3D and its products, visit the Nexa3D website, or connect socially on LinkedIn, Twitter, Facebook, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom